About Us
Telix Pharmaceuticals was created to deliver on the promise of nuclear medicine
The field of nuclear medicine has historically lacked clinical momentum and commitment to late-stage product development. Our goal is to rectify this for the benefit of patients.
)
First U.S. Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 25th January 2021. Telix Pharmaceuticals announces the first U.S. patients have been dosed...
Telix Pharmaceuticals Appoints Danielle Meyrick MD as CMO, Asia-Pacific
22nd January 2021 – Corporate Spotlight | Telix Pharmaceuticals welcomes Dr Danielle Meyrick as Chief Medical Officer, Asia Pacific
ARTMS and Telix Pharmaceuticals Announce Successful Production of 68Ga PSMA-11 with Cyclotron Produced 68Ga from a Solid Target
Burnaby, Canada and Indianapolis, USA, January 12, 2021 – ARTMS Inc. and Telix announce successful production of Telix’s prostate cancer...
Telix Pharmaceuticals and Mauna Kea Technologies Launch Urologic Oncology Alliance
Melbourne (Australia) – 16th December 2020. Telix Pharmaceuticals announces collaboration with Mauna Kea Technologies to develop advanced image-guided surgical technologies in the field...